Results 111 to 120 of about 12,336,620 (246)

Biomarkers Predicting Sustained Unresponsiveness After Oral Immunotherapy in the OPIA Trial

Allergy, EarlyView.
Duan Ni, Gabriela Pinget, Brigitte Santner‐Nanan, Catherine L. Lai, Laurence Macia, Dianne E. Campbell, Peter Hsu, Ralph Nanan   +7 more
wiley   +1 more source

Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma

British Journal of Haematology, EarlyView.
After adjusting for confounders, the ibrutinib cohort had significantly better overall survival (adjusted hazard ratio, 0.39; 95% confidence interval, 0.23–0.68; p = 0.0008) than the allogeneic haematopoietic stem cell transplantation (alloHSCT) cohort.
Farrukh T. Awan, Ran Liu, Hsin‐Hui Huang, Matthew Bye, Kwang Woo Ahn, Gabriel Krigsfeld, Anat Raz, Heather Wolfe, Mehdi Hamadani   +8 more
wiley   +1 more source

Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance. [PDF]

Sci Rep, 2020
Calvo T, Reina-Ortiz C, Giraldos D, Gascón M, Woods D, Asenjo J, Marco-Brualla J, Azaceta G, Izquierdo I, Palomera L, Sánchez-Martínez D, Marzo I, Naval J, Vilches C, Villalba M, Anel A.   +15 more
europepmc   +1 more source

Antigen-specific B cell responses in treatment-naive and chlorambucil-treated patients with chronic lymphocytic leukemia

Scientific Reports
Chronic lymphocytic leukemia (CLL) is characterized by secondary immunodeficiency, yet the extent to which global disease-associated immune dysregulation impairs the ability to generate antigen-specific B cell immunity—independent of targeted therapy ...
Baiba Šlisere, Roberts Kārkliņš, Aiga Plēgermane, Eva E. Morozova, Ramona Petrovska, Dace Pjanova, Sandra Lejniece, Kristīne Oļeiņika   +7 more
doaj   +1 more source

Cytokine Release Ensuing Interaction Between Human Peripheral Blood Mononuclears and Epstein-Barr Virus Transformed B-CLL Cell Line. [PDF]

J Immunother Precis Oncol, 2020
Bessler H, Leibovitch CM, Djaldetti M.
europepmc   +1 more source

CLL patients with TP53 abnormalities.

, 2015
The assessment of the functional status of P53 in CLL cells was based on induction of P21 and P53 protein expression using etoposide and nutlin-3a [39]. The detection of TP53 mutations was performed as described in Methods.
Elise Chapiro (199844), Laura Vela (697378), Roba Moumné (697382), Linda Herbi (697377), Hélène Merle-Béral (284685), Magali Le Garff-Tavernier (284681), Danielle Chateau (374940), Frédéric Davi (697381), Philippe Karoyan (697383), Marika Sarfati (145927), Sandrine Barbier (697379), Ana-Carolina Martinez-Torres (697374), Pierre Launay (280563), Santos A. Susin (697384), Tarik Attout (112432), Claire Quiney (697375), Heloïse Boullet (697376), Florence Nguyen-Khac (697380)   +17 more
core   +1 more source

Dynamic risk stratification using early CAR‐T expansion in R/R LBCL treated with axicabtagene ciloleucel

British Journal of Haematology, EarlyView.
Higher chimeric antigen receptor‐T expansion at day 7 is associated with improved progression‐free survival but also increased toxicity in axi‐cel treated patients with R/R large B‐cell lymphoma, independent of other baseline patient and disease characteristics.
Brydon Panozzo, Samuel Robinson, Adrian G. Minson, Jian Li, Kylie Baldwin, Hamish W. Scott, Jane Oliaro, Aaron J. N. Wong, Samantha van der Linde, Nicole L. O'Leary, Philip A. Thompson, John F. Seymour, Mary Ann Anderson, Constantine S. Tam, Simon J. Harrison, Michael J. Dickinson, David A. Westerman, Mark R. Dowling   +17 more
wiley   +1 more source

Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL)

, 1995
SUMMARY It has previously been reported that the expression of the complement receptors CRI (CD35) and CR2 (CD21) on malignant B cells in CLL is reduced compared with the expression on normal B cells, while deposition of complement C3 ...
S-E Svehag, R G Q Leslie, H V Marquart, B E Christensen, K GrØNbÆEk   +4 more
core   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

hTERT, CD23 und CD229 als Tumorantigene bei der B-CLL [PDF]

, 2012
Eine kritische Vorraussetzung für eine effektive Krebstherapie stellt die Identifizierung von Tumor-spezifischen oder Tumor-assoziierten Antigenen (TAAs) dar. Diese Antigene sollten Peptidsequenzen besitzen, die an MHC-Moleküle binden. Auch sollten diese
Bund, Dagmar
core   +1 more source